-
Spain to cap gas price hikes, extend fuel discounts
-
Stocks move sideways despite oil moving lower
-
'We just need rain': Germany's Rhine river hits new low
-
African leaders to gather in Egypt for business summit
-
Yemen health system at 'breaking point': WHO
-
UK decides against charging foreign visitors for museums
-
Ireland undecided on second Israel match: coach
-
Dallaglio to sell England World Cup winners' medal
-
France's Le Pen defiant after top ally hit by antisemitism claims
-
Brazil come from behind to beat Australia 4-2 in friendly
-
Tom Cruise trades stunts for satire as toxic tycoon 'Digger'
-
Ruthless An retains Asian Games badminton crown as Kunlavut triumphs
-
MEXC Unveils "WE SEE YOU" Brand Visual Refresh, Putting People Behind Every Trade in Focus
-
Alonso to stay with F1 team Aston Martin in 2027
-
Thai capital cleans up after deadly floods
-
China badminton 'still strong' despite Asian Games slump
-
NATO, EU allies rally to Estonia after 'sabotage' blamed on Russia
-
'Exceptional' Turner painting shown in Rome before sale
-
Families demand justice for Cameroon's 'nightmare' wave of murdered women
-
European stocks climb as oil dips
-
Tebas says Man City should face 'most severe' sanctions if guilty of rule breaches
-
Spain aims to ban evictions until 2030 amid housing protests
-
Pochettino calls Man City success 'a period of deception'
-
Kunlavut first Thai man to win Asian Games badminton singles gold
-
Settler attack on West Bank village injures Israeli forces, drawing rare rebuke
-
French far right says antisemitism claims part of 'total war' to derail presidency bid
-
Mystery over UK airbase scare after reports no explosives found
-
'Gift from God': Rain brings relief from Indonesia toxic haze
-
Spanish govt races to adopt housing law under protest pressure
-
Ex-world snooker champion jailed for 7 years for child sex crimes
-
Estonia slams Russian 'sabotage' after arson attack on defence company
-
French teens clash with police as school blockades intensify
-
Slovenia sees surge in '.si' sites after Trump hypes 'super intelligence'
-
FIFA accuses UEFA of 'misinformation campaign' in bid for World Cup papers
-
'Like a dream' for An as Games organisers 'sorry' for latest mix-up
-
Myanmar airstrike toll hits 50 as families gather dead
-
Tokyo suffers longest streak of rainy days on record
-
STARTRADER Raises Lloyd's of London Client Fund Insurance to USD 30 Million in Aggregate
-
Indonesia charges train driver over crash that killed 16 women
-
North Korean DMZ landmine blasts 'violation of armistice': Seoul
-
Ruthless An makes history to retain Asian Games badminton crown
-
Sabalenka 'fresh' for first tournament since losing No.1 spot
-
Australian central bank lifts key interest rate to 15-year high
-
Myanmar airstrike death toll rises to 50: aid workers
-
Polo makes landfall in Mexico as Category 3 hurricane
-
North Korean DMZ landmine blast 'violation of armistice'
-
South Korea team latest to be bussed to wrong Asian Games venue
-
South Korea volleyball team latest to be bussed to wrong Games venue
-
Bears thrash Eagles 27-7 as third-string QB Keenum shines
-
Malaysia starts sending Myanmar migrants home
First person vaccinated during trial of new Ebola jab
A volunteer was injected on Friday with the first dose of a rapidly developed vaccine targeting the Bundibugyo strain of Ebola driving a deadly outbreak in the Democratic Republic of Congo, Oxford University said.
More than 1,000 people have been killed in the DRC and Uganda since the outbreak emerged in May, according to the World Health Organization.
Researchers and health organisations have since been racing to get a vaccine or treatment for the relatively rare strain to the clinical trial stage where it is tested on humans.
Earlier this month, a team at Oxford University in the UK announced it was launching the first trial for its ChAdOx1 BDBV vaccine, which uses the same technology as AstraZeneca's Covid-19 vaccine.
The first dose was administered to a 37-year-old volunteer named Ed Hunt in Oxford on Friday, a university spokesman told AFP.
"We've taken this vaccine candidate from concept to clinic in just eight weeks," David Pulido-Gomez of Oxford's Pandemic Sciences Institute said in a statement.
"Reaching this milestone in such a short timeframe reflects an extraordinary collaborative effort," he added.
The trial received funding from the Coalition for Epidemic Preparedness Innovations (CEPI), while the Serum Institute of India has already manufactured a stockpile of 620,000 doses.
The phase 1 trial plans to assess the safety and effectiveness of the vaccine in 50 health adults in the coming weeks. The researchers are currently recruiting more volunteers.
Given regulatory approval, the team is preparing for more clinical studies of the vaccine with partners in Uganda, Oxford said.
Several other Bundibugyo vaccine candidates are also being urgently developed towards the trial stage, while two potential treatments are being worked on.
The Ebola outbreak is the 17th in the DRC's history, but just the third caused by the Bundibugyo strain, for which there are no approved vaccines or treatments.
WHO chief Tedros Adhanom Ghebreyesus warned last week that the outbreak had over the past month "expanded faster than any previous outbreak" of Ebola.
The outbreak has remained concentrated in the vast country's mineral-rich and conflict-plagued northeastern province.
Cases of Ebola, which spreads through close contact and infected bodily fluids, have also been found in four other DRC provinces.
M.Furrer--BTB